Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial
Authors:
- 6 November 2023
- journal article
- letter
- Published by Elsevier in Oral Oncology
- Vol. 147, 106620
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal CancerCancers, 2022
- Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancerEuropean Journal of Cancer, 2022
- Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivityNature Communications, 2021
- Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV MelanomaCancers, 2021
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast CancerJAMA Network Open, 2020
- Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic reviewCancer Treatment Reviews, 2020
- Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and ProcessesThe Journal of Molecular Diagnostics, 2020
- Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor materialBMC Cancer, 2020
- Circulating tumor DNA and liquid biopsy in oncologyNature Cancer, 2020
- About the possible origin and mechanism of circulating DNAClinica Chimica Acta, 2001